SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Idenix Pharmaceuticals (IDIX)
An SI Board Since March 2004
Posts SubjectMarks Bans Symbol
412 15 0 IDIX
Emcee:  michael_f_murphy Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
412New 3 yr highs. finance.yahoo.comsemi_infinite -11/17/2011
411Adam Feuerstein writes about who has been buying. thestreet.comsemi_infinite -8/17/2011
410The stock is acting like there is something positive happening with the pipelinesemi_infinite -7/11/2011
409IDIX completed bioavailability study for oral formulation of 184. Big whoop. Atuck-4/27/2011
408Mom ain't buyin' nuthin' right now. She's waiting for weakness tuck-4/15/2011
407<i> I have taken that gift to boot this out of my Mom's portfolio thisSteve Lokness14/15/2011
406With its clinical candidates dead except for 184, which is single in an HCV marktuck-4/15/2011
405I remember that. A few others might have come to the same conclusion, but judgituck-2/9/2011
404<i>>That the candidates other than 184 were in trouble seemed <b>DewDiligence_on_SI-2/9/2011
403>>Idenix Pharmaceuticals Provides Updates on Three Clinical Development Prtuck-2/9/2011
402The Separation Agreement provides Dr. Sommadossi with severance benefits commensscaram(o)uche-12/30/2010
401IDIX ‘ReadMeFirst’ updated: <i>2Q10 financial results; liquidity and cashDewDiligence_on_SI-8/16/2010
400IDIX ‘ReadMeFirst’ updated: <i>IDX184+IDX320 DDI study begins; 2010-2011 DewDiligence_on_SI-7/19/2010
399Please ignore msg #398.DewDiligence_on_SI-7/19/2010
398IDIX <i>ReadMeFirst</i> updated: <i>IDX184+IDX320 DDI study bDewDiligence_on_SI-7/19/2010
397IDIX 2010-2011 News Flow: <i>Updated info for IDX184+IDX320 DDI study.&lDewDiligence_on_SI-7/7/2010
396IDIX <i>ReadMeFirst</i> updated: <i>new version of “Who’s WhoDewDiligence_on_SI-6/20/2010
395IDIX <i>ReadMeFirst</i> updated: <i>who’s who in all-oral HCVDewDiligence_on_SI-6/13/2010
394IDIX <i> ReadMeFirst</i> updated: <i>start of phase-1b (proofDewDiligence_on_SI-6/10/2010
393tnsaf: DR’s forecasts for the size of the HCV market are indeed “interesting” (wDewDiligence_on_SI-5/24/2010
392Dew, the C&EN article is interesting for its reminder of the likely future otnsaf-5/24/2010
391IDIX ‘ReadMeFirst’ updated: <i>text of Thomas Weisel report with $9 priceDewDiligence_on_SI-5/24/2010
390Text from Thomas Weisel’s report with $9 target: siliconinvestor.comDewDiligence_on_SI-5/24/2010
389T Rowe Price now has an 11% stake, FWIW: sec.gov Updated table of major sharehoDewDiligence_on_SI-5/10/2010
388IDIX ‘ReadMeFirst’ updated: <i>all-oral HCV cocktail of IDX184+IDX320; 20DewDiligence_on_SI-5/4/2010
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News